Ankylosing Spondylitis

A review of 75 adalimumab clinical trials in adult and pediatric patients demonstrated low rates of inflammatory bowel disease adverse events, according to data published in Arthritis Care & Research.

SCOTTSDALE, Ariz. — IL-23 drives IL-17 production. IL-17 inhibition is effective in ankylosing spondylitis. However, evidence has shown that IL-23 or IL-12/23 inhibition is not necessarily effective in AS.

The FDA has approved a label update for secukinumab, allowing the option for a higher 300 mg dose among adults with active ankylosing spondylitis based on clinical response.

There is an increased risk for developing inflammatory arthritis among patients with hidradenitis suppurativa, according to a population-based cohort study published in JAMA Dermatology.

Patients with ankylosing spondylitis demonstrate a distinct fecal microbiota signature that is linked to levels of fecal calprotectin, but not other clinical parameters, according to data published in Arthritis Research & Therapy.

The investigational IL-17A and IL-17F inhibitor bimekizumab was superior to adalimumab in achieving a 90% improvement in Psoriasis Area and Severity Index score after 16 weeks, according to a press release from UCB.

ATLANTA — Certolizumab pegol and bimekizumab were associated with improvements ranging from work productivity to disease activity in patients with spondyloarthritic conditions, according to findings presented in three abstracts at ACR/ARP 2019.

ATLANTA — Ixekizumab combined with conventional background medication is superior to both conventional background medication alone and placebo in improving signs, symptoms and inflammation based on MRI among patients with nonradiographic axial spondyloarthritis, according to data presented at ACR/ARP 2019.

ATLANTA — A daily regimen of 15 mg upadacitinib was significantly more effective than placebo in improving signs, symptoms, function and imaging among patients with active ankylosing spondylitis, according to the presenter at ACR/ARP 2019.

ATLANTA — The use of either non-TNF inhibitor biologics or tofacitinib for chronic inflammatory diseases during pregnancy did not significantly increase risk for serious infections among infants, according to findings presented at the 2019 ACR/ARP Annual Meeting.